STARTINA 5 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

startina 5 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - acetilsalicilna kiselina, rosuvastatin - kapsula, tvrda - 5 mg/1 kapsula+ 100 mg/1 kapsula - 1 kapsula, tvrda sadrži 5 mg rosuvastatina (u obliku rosuvastatinkalcijuma) i 100 mg acetilsalicilne kiseline

STARTINA 10 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

startina 10 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - acetilsalicilna kiselina, rosuvastatin - kapsula, tvrda - 10 mg/1 kapsula+ 100 mg/1 kapsula - 1 kapsula, tvrda sadrži 10 mg rosuvastatina (u obliku rosuvastatinkalcijuma) i 100 mg acetilsalicilne kiseline

STARTINA 20 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

startina 20 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - acetilsalicilna kiselina, rosuvastatin - kapsula, tvrda - 20 mg/1 kapsula+ 100 mg/1 kapsula - 1 kapsula, tvrda sadrži 20 mg rosuvastatina (u obliku rosuvastatinkalcijuma) i 100 mg acetilsalicilne kiseline

DuoPlavin Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

duoplavin

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitrombotska sredstva - duoplavin je indiciran za sekundarnu prevenciju aterotrombotskih događaja u bolesnika odraslih koji već uzimaju i klopidogrel i acetilsalicilnu kiselinu (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. za više informacija, molimo pogledajte odjeljak 5.

Granupas (previously Para-aminosalicylic acid Lucane) Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

granupas (previously para-aminosalicylic acid lucane)

eurocept international b. v. - par-аминосалициловая kiselina - tuberkuloza - antimikobakterija - granupas je indiciran za uporabu kao dio odgovarajući kombiniranom za multi-rezistentna tuberkuloza u odraslih i pedijatrijskih bolesnika od 28 dana starosti i starije kada učinkovite terapije ne može inače biti sastoji iz razloga otpor ili podnošljivost (vidjeti dio 4.. treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika.

Deep Heat sprej za kožu, otopina Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

deep heat sprej za kožu, otopina

the mentholatum company limited, 1 redwood avenue, peel park campus, east kilbride, ujedinjeno kraljevstvo - methylis nicotinas, salicylas hydroxyethylis, methylis salicylas, ethylis salicylas - sprej za kožu, otopina - 1,6 %, 5,0 %, 1,0 % i 5,0 % (m/m) - urbroj: 100 g sprej otopine sadržava: metilnikotinat 1,6%, hidroksietilsalicilat 5,0%, metilsalicilat 1,0%, etilsalicilat 5,0%

GRIPPOSTAD COMPLEX 30 mg/1 kesica+ 500 mg/1 kesica granule za oralnu suspenziju Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

grippostad complex 30 mg/1 kesica+ 500 mg/1 kesica granule za oralnu suspenziju

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - acetil salicilna kiselina, pseudoefedrin - granule za oralnu suspenziju - 30 mg/1 kesica+ 500 mg/1 kesica - jedna kesica sadrži: 30 mg pseudoefedrinhidrohlorida i 500 mg acetilsalicilne kiseline.

Acekal C 500 mg + 300 mg šumeći prašak s okusom limuna Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

acekal c 500 mg + 300 mg šumeći prašak s okusom limuna

fidifarm d.o.o., obrtnička 37, rakitje, bestovje - folna acetylsalicylicum, ascorbicum ацидум - šumeći prašak - 500 mg + 300 mg - urbroj: jedna vrećica sadrži 500 mg acetilsalicilatne kiseline i 300 mg askorbatne kiseline

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.